Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Empiriko, Interchim Sign Partnership Agreement

Published: Thursday, February 27, 2014
Last Updated: Thursday, February 27, 2014
Bookmark and Share
Empiriko will leverage Interchim's PuriFlash®/MassSpec technology to conduct in vitro and ex-vivo drug metabolism studies using its Biomimiks™ technology.

By leveraging the powerful combination of Empiriko's game-changing chemosynthetic livers and Interchim's innovative instrumentation and expertise in the field of liquid chromatography, pharmaceutical scientists can now predict metabolism patterns, pathways and profiles -- all while generating a complete spectrum of oxidative metabolites for specific drugs and reducing the time for each experiment from weeks to hours. Additionally, scientists and clinicians can quickly identify interactions involving metabolite attenuation and suppression, and evaluate the genotoxicity, drug-to-drug interactions and efficacy associated with adding a new drug to a patient's drug regimen. Interchim's latest PuriFlash® instruments incorporate a mass spectrometer which allows near real-time product separation and structural elucidation of purified compounds and is ideally suited to support Empiriko's Biomimiks technology.

"Our partnership with Interchim represents an important step forward for both companies," said Mukund Chorghade, Empiriko's Chief Scientific Officer. "We are able to offer more comprehensive drug discovery and clinical research solutions and results. Together we will accelerate the delineation of metabolism profiles, enable prediction and scale-up of products and offer scientists a valuable tool for rapid separation and quantification of products. We look forward to working with Interchim to advance the boundaries of DMPK studies."

Also under the agreement, Empiriko will provide input to Interchim with regard to the design of future instrumentation for ex-vivo studies geared toward personalized patient treatment. Empiriko's unprecedented approach to drug testing will drive efficiencies and cost savings, helping pharmaceutical companies realize the next generation of discoveries.

"In a manner of minutes, we were able to generate and isolate metabolites for pharmaceutical entities using Empiriko's Biomimiks™ catalyst and our PuriFlash instrument," added Geoff Todosiev, President of Interchim, Inc. "It was remarkable to observe our instruments being used in such an innovative manner. This partnership opens a whole new market for Interchim's instruments to be used in new applications and we're excited about our ongoing work together."

"Pharmaceutical companies are eager to propel advances in drug discovery and clinical development under continued budget and timeline constraints, and we're determined to help alleviate these top challenges," said Pam Randhawa, Empiriko's CEO. "Interchim's technology will play an important role in helping us fulfill our vision throughout the entire drug lifecycle -- evaluating new chemical entities for drug discovery and clinical trials, as well as personalized patient treatment. No doubt we are working under a new paradigm -- and it is an incredibly exciting time."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Biological Link between the Gut Microbiome and Parkinson’s Disease
The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating Parkinson’s disease.
How the Brain Recognizes Faces
Machine-learning system spontaneously reproduces aspects of human neurology.
Boosting Effectiveness of Asthma Therapy
A team of scientists from UCSF has developed a new treatment to dampen bronchospasm.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!